Global Aflibercept Biosimilars Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Aflibercept Biosimilars market size will reach 10,407 Million USD in 2025 and is projected to reach 11,574 Million USD by 2032, with a CAGR of 1.53% (2025-2032). Notably, the China Aflibercept Biosimilars market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Aflibercept biosimilars are biologic medical products highly similar to the original aflibercept (marketed as Eylea), which is an anti-VEGF (vascular endothelial growth factor) therapy used primarily to treat various retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. These biosimilars undergo rigorous testing to demonstrate their equivalence in terms of safety, efficacy, and quality to the reference product, providing more cost-effective treatment options while maintaining therapeutic benefits for patients suffering from serious eye conditions that can lead to vision loss.
The major global manufacturers of Aflibercept Biosimilars include Bayer, Roche, Regeneron, Sanofi, Novartis, Sartorius, Amgen, Samsung Bioepis, Mylan, Formycon, Coherus BioSciences, Cadila Pharmaceuticals, Hetero, Biocon, Gene Techno Science, Qilu Pharmaceutical, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Aflibercept Biosimilars. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Aflibercept Biosimilars market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Aflibercept Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Aflibercept Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Aflibercept Biosimilars Include:
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Aflibercept Biosimilars Product Segment Include:
Intravitreal Injection
Intravenous Injection
Aflibercept Biosimilars Product Application Include:
Wet Macular Degeneration
Metastatic Colorectal Cancer
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Aflibercept Biosimilars Industry PESTEL Analysis
Chapter 3: Global Aflibercept Biosimilars Industry Porter's Five Forces Analysis
Chapter 4: Global Aflibercept Biosimilars Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Aflibercept Biosimilars Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Aflibercept Biosimilars Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Aflibercept Biosimilars Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Aflibercept Biosimilars market size will reach 10,407 Million USD in 2025 and is projected to reach 11,574 Million USD by 2032, with a CAGR of 1.53% (2025-2032). Notably, the China Aflibercept Biosimilars market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Aflibercept biosimilars are biologic medical products highly similar to the original aflibercept (marketed as Eylea), which is an anti-VEGF (vascular endothelial growth factor) therapy used primarily to treat various retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. These biosimilars undergo rigorous testing to demonstrate their equivalence in terms of safety, efficacy, and quality to the reference product, providing more cost-effective treatment options while maintaining therapeutic benefits for patients suffering from serious eye conditions that can lead to vision loss.
The major global manufacturers of Aflibercept Biosimilars include Bayer, Roche, Regeneron, Sanofi, Novartis, Sartorius, Amgen, Samsung Bioepis, Mylan, Formycon, Coherus BioSciences, Cadila Pharmaceuticals, Hetero, Biocon, Gene Techno Science, Qilu Pharmaceutical, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Aflibercept Biosimilars. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Aflibercept Biosimilars market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Aflibercept Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Aflibercept Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Aflibercept Biosimilars Include:
Bayer
Roche
Regeneron
Sanofi
Novartis
Sartorius
Amgen
Samsung Bioepis
Mylan
Formycon
Coherus BioSciences
Cadila Pharmaceuticals
Hetero
Biocon
Gene Techno Science
Qilu Pharmaceutical
Aflibercept Biosimilars Product Segment Include:
Intravitreal Injection
Intravenous Injection
Aflibercept Biosimilars Product Application Include:
Wet Macular Degeneration
Metastatic Colorectal Cancer
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Aflibercept Biosimilars Industry PESTEL Analysis
Chapter 3: Global Aflibercept Biosimilars Industry Porter's Five Forces Analysis
Chapter 4: Global Aflibercept Biosimilars Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global Aflibercept Biosimilars Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global Aflibercept Biosimilars Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, Aflibercept Biosimilars Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Aflibercept Biosimilars Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Aflibercept Biosimilars Product by Type
- 1.2.1 Intravitreal Injection
- 1.2.2 Intravenous Injection
- 1.3 Aflibercept Biosimilars Product by Application
- 1.3.1 Wet Macular Degeneration
- 1.3.2 Metastatic Colorectal Cancer
- 1.4 Global Aflibercept Biosimilars Market Revenue and Sales Analysis
- 1.4.1 Global Aflibercept Biosimilars Revenue Market Size Analysis (2020-2032)
- 1.4.2 Global Aflibercept Biosimilars Sales Market Size Analysis (2020-2032)
- 1.4.3 Global Aflibercept Biosimilars Market Sales Price Trend Analysis (2020-2032)
- 1.5 Aflibercept Biosimilars Market Development Status and Trends
- 1.5.1 Aflibercept Biosimilars Industry Development Status Analysis
- 1.5.2 Aflibercept Biosimilars Industry Development Trends Analysis
- 2 Aflibercept Biosimilars Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Aflibercept Biosimilars Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Aflibercept Biosimilars Market Analysis by Country
- 4.1 Global Aflibercept Biosimilars Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Aflibercept Biosimilars Revenue and Market Share by Country (2020-2025)
- 4.1.2 Global Aflibercept Biosimilars Revenue and Market Share Forecast by Country (2026-2032)
- 4.2 Global Aflibercept Biosimilars Sales Analysis by Country: 2024 VS 2025 VS 2032
- 4.2.1 Global Aflibercept Biosimilars Sales and Market Share by Country (2020-2025)
- 4.2.2 Global Aflibercept Biosimilars Sales and Market Share Forecast by Country (2026-2032)
- 4.3 United States Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.4 Germany Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.5 Japan Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.6 China Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.7 France Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.8 U.K. Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.9 South Korea Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.10 Canada Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.11 Italy Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.12 Russia Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.13 Mexico Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.14 Brazil Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.15 India Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.16 Vietnam Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.17 Thailand Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 4.18 South Africa Aflibercept Biosimilars Market Sales, Revenue and Growth Rate (2020-2032)
- 5 Competition by Manufacturers
- 5.1 Global Aflibercept Biosimilars Market Sales, Revenue and Sales Price by Key Manufacturers (2021-2025)
- 5.1.1 Global Aflibercept Biosimilars Market Sales by Key Manufacturers (2021-2025)
- 5.1.2 Global Aflibercept Biosimilars Market Revenue by Key Manufacturers (2021-2025)
- 5.1.3 Global Aflibercept Biosimilars Average Sales Price by Manufacturers (2021-2025)
- 5.2 Aflibercept Biosimilars Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Aflibercept Biosimilars Competitive Landscape Analysis
- 5.2.2 Global Key Manufacturers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Aflibercept Biosimilars Market Analysis by Type
- 6.1 Global Aflibercept Biosimilars Market Revenue Analysis by Type
- 6.1.1 Global Aflibercept Biosimilars Market Size Analysis by Type: 2024 & 2025 & 2032
- 6.1.2 Global Aflibercept Biosimilars Revenue and Forecast Analysis by Type (2020-2032)
- 6.2 Global Aflibercept Biosimilars Market Sales and Forecast Analysis by Type (2020-2032)
- 6.3 Global Aflibercept Biosimilars Sales Price Trend Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Bayer
- 7.1.1 Bayer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Bayer Aflibercept Biosimilars Product Portfolio
- 7.1.3 Bayer Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.2 Roche
- 7.2.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Roche Aflibercept Biosimilars Product Portfolio
- 7.2.3 Roche Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.3 Regeneron
- 7.3.1 Regeneron Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Regeneron Aflibercept Biosimilars Product Portfolio
- 7.3.3 Regeneron Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.4 Sanofi
- 7.4.1 Sanofi Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Sanofi Aflibercept Biosimilars Product Portfolio
- 7.4.3 Sanofi Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.5 Novartis
- 7.5.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Novartis Aflibercept Biosimilars Product Portfolio
- 7.5.3 Novartis Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.6 Sartorius
- 7.6.1 Sartorius Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Sartorius Aflibercept Biosimilars Product Portfolio
- 7.6.3 Sartorius Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.7 Amgen
- 7.7.1 Amgen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Amgen Aflibercept Biosimilars Product Portfolio
- 7.7.3 Amgen Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.8 Samsung Bioepis
- 7.8.1 Samsung Bioepis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Samsung Bioepis Aflibercept Biosimilars Product Portfolio
- 7.8.3 Samsung Bioepis Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.9 Mylan
- 7.9.1 Mylan Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Mylan Aflibercept Biosimilars Product Portfolio
- 7.9.3 Mylan Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.10 Formycon
- 7.10.1 Formycon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Formycon Aflibercept Biosimilars Product Portfolio
- 7.10.3 Formycon Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.11 Coherus BioSciences
- 7.11.1 Coherus BioSciences Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Coherus BioSciences Aflibercept Biosimilars Product Portfolio
- 7.11.3 Coherus BioSciences Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.12 Cadila Pharmaceuticals
- 7.12.1 Cadila Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Cadila Pharmaceuticals Aflibercept Biosimilars Product Portfolio
- 7.12.3 Cadila Pharmaceuticals Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.13 Hetero
- 7.13.1 Hetero Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Hetero Aflibercept Biosimilars Product Portfolio
- 7.13.3 Hetero Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.14 Biocon
- 7.14.1 Biocon Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 Biocon Aflibercept Biosimilars Product Portfolio
- 7.14.3 Biocon Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.15 Gene Techno Science
- 7.15.1 Gene Techno Science Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.15.2 Gene Techno Science Aflibercept Biosimilars Product Portfolio
- 7.15.3 Gene Techno Science Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 7.16 Qilu Pharmaceutical
- 7.16.1 Qilu Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.16.2 Qilu Pharmaceutical Aflibercept Biosimilars Product Portfolio
- 7.16.3 Qilu Pharmaceutical Aflibercept Biosimilars Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Aflibercept Biosimilars Industry Chain Analysis
- 8.2 Aflibercept Biosimilars Industry Upstream Supply Analysis
- 8.2.1 Upstream Key Raw Material Supply Analysis
- 8.2.2 Raw Material Suppliers and Contact Information
- 8.3 Aflibercept Biosimilars Product Downstream Application Analysis
- 8.3.1 Global Aflibercept Biosimilars Revenue Market Size by Application: 2024 & 2025 & 2032
- 8.3.2 Global Aflibercept Biosimilars Revenue and Forecast Analysis by Application (2020-2032)
- 8.3.3 Global Aflibercept Biosimilars Sales and Forecast Analysis by Application (2020-2032)
- 8.4 Aflibercept Biosimilars Typical Downstream Customers
- 8.5 Aflibercept Biosimilars Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
